Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading on Wednesday. Traders purchased 5,247 call options on the stock. This is an increase of approximately 964% compared to the typical daily volume of 493 call options.

Maravai LifeSciences Stock Down 2.3 %

MRVI traded down $0.06 during trading on Thursday, reaching $2.38. The company had a trading volume of 871,811 shares, compared to its average volume of 3,089,368. The business’s fifty day moving average price is $4.09 and its 200 day moving average price is $5.90. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences has a 12 month low of $2.25 and a 12 month high of $11.56. The company has a market cap of $599.75 million, a P/E ratio of -1.45 and a beta of -0.08.

Wall Street Analysts Forecast Growth

MRVI has been the topic of several analyst reports. The Goldman Sachs Group lowered shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price objective for the company from $7.00 to $4.25 in a report on Thursday, December 5th. Bank of America reduced their price target on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $9.00 to $3.00 in a report on Wednesday, February 26th. Guggenheim initiated coverage on Maravai LifeSciences in a report on Thursday, December 19th. They set a “neutral” rating on the stock. Finally, Baird R W cut Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, Maravai LifeSciences currently has an average rating of “Hold” and a consensus target price of $9.28.

Insiders Place Their Bets

In related news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the sale, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently added to or reduced their stakes in MRVI. Alpha Wealth Funds LLC bought a new stake in shares of Maravai LifeSciences in the fourth quarter valued at about $386,000. Delta Investment Management LLC raised its position in Maravai LifeSciences by 285.4% in the 4th quarter. Delta Investment Management LLC now owns 332,993 shares of the company’s stock valued at $1,815,000 after buying an additional 246,592 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Maravai LifeSciences by 22.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company’s stock valued at $1,369,000 after acquiring an additional 45,454 shares in the last quarter. Systematic Financial Management LP boosted its position in Maravai LifeSciences by 2.3% during the 4th quarter. Systematic Financial Management LP now owns 1,649,544 shares of the company’s stock worth $8,990,000 after acquiring an additional 37,383 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of Maravai LifeSciences during the 4th quarter worth approximately $78,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.